Stuart L. Goldstein, MD, has been an active investigator in the field of pediatric acute kidney injury (AKI) since 2000. Dr. Goldstein’s main research foci include: AKI epidemiology and outcomes, acute renal replacement therapy provision and investigation of novel urinary AKI biomarkers in the pediatric population. Dr. Goldstein has established a strong record of interdisciplinary and inter-institutional collaboration with cardiologists, intensivists and emergency center physicians, which is evidenced by his establishment and directing of the Prospective Pediatric Continuous Renal Replacement Therapy Registry from 2001 to 2012, and the Prospective Pediatric AKI Research Group (ppAKI-RG) in 2012. The ppAKI-RG is comprised of 39 centers from around the world with the goal of improving outcomes for the child with or at-risk for, AKI.
Dr. Goldstein has led initial efforts to develop a standardized definition for pediatric AKI, assess novel AKI biomarkers in heterogeneous populations, and conceiving and validating stratification tools to identify patients at risk for AKI. Building up these findings, Dr. Goldstein embarked on establishing the ppAKI-RG consortium to focus on multi-centered research studies that are dedicated to understanding and treating AKI in pediatric patients. Currently, the ppAKI-RG has initiated three major, and unprecedented, national and international studies (AWARE, NINJA and DIRECT) to reduce AKI and improve patient outcomes. Dr. Goldstein is also a recognized educator; he has developed the only pediatric specific acute care nephrology sub-specialty fellowship with graduates who are now leaders in the field of pediatric AKI.